5 ms·

In 2018 itself, 23andMe had a partnership with GSK > As part of the collaboration, GSK can also change the way we invite patients into clinical trials. The gen

In 2018 itself, 23andMe had a partnership with GSK > As part of the collaboration, GSK can also change the way we invite patients into clinical trials. The genetic and disease information 23andMe customers share will allow us to identify the kind of patients who are most likely to respond well to new treatments so that 23andMe can invite customers who have consented to be contacted to participate in studies that are relevant to them. This could significantly shorten recruitment and reduce clinical development timelines, allowing some medicines to be delivered to patients faster. https://us.gsk.com/en-us/behind-the-science/innovation/you-me-and-23andme-discovering-new-medicines-through-genetics/ https://us.gsk.com/en-us/behind-the-science/innovation/you-m... I'm not sure what the "news" is.

tpmx 5y ago
They're probably in the news because quarterly results are released in two days. Their core product is facing a retracting market (partially) because of privacy concerns. Number of genotyped customers: FY18A: 2.4M FY19A: 3.4M FY20A: 2.0M FY21A: 1.5M FY22Q1: 0.3M Numbers from https://investors.23andme.com/static-files/8db681b8-4ea3-452f-a3e6-3a151d8866d9 https://investors.23andme.com/static-files/8db681b8-4ea3-452... (page 11)
- dnissley 5y ago
  How do you know it's because of privacy concerns and not because they've exhausted the market of people who want to know about this kind of info? This is very much a one and done type of product -- in fact, the reason I myself haven't gone ahead and done it is because my parents and grandparents have already gotten it done, and I've looked over their results, so I'm assuming there's very little I could learn about myself from it.
  - tpmx 5y ago
    Possibly a combination of privacy concerns and running out of early adopters? Wojcicki claimed it was the privacy concerns in a WSJ interview from 2019: https://archive.md/E1Zqw https://archive.md/E1Zqw
  - dhosek 5y ago
    You could learn about a non-paternal event, I suppose.
    - dymk 5y ago
      That’s literally why I did 23andme, and I found out some very interesting things about my family structure.

tpmx 5y ago

They're probably in the news because quarterly results are released in two days. Their core product is facing a retracting market (partially) because of privacy concerns. Number of genotyped customers: FY18A: 2.4M FY19A: 3.4M FY20A: 2.0M FY21A: 1.5M FY22Q1: 0.3M Numbers from https://investors.23andme.com/static-files/8db681b8-4ea3-452f-a3e6-3a151d8866d9 https://investors.23andme.com/static-files/8db681b8-4ea3-452... (page 11)

dnissley 5y ago
How do you know it's because of privacy concerns and not because they've exhausted the market of people who want to know about this kind of info? This is very much a one and done type of product -- in fact, the reason I myself haven't gone ahead and done it is because my parents and grandparents have already gotten it done, and I've looked over their results, so I'm assuming there's very little I could learn about myself from it.
- tpmx 5y ago
  Possibly a combination of privacy concerns and running out of early adopters? Wojcicki claimed it was the privacy concerns in a WSJ interview from 2019: https://archive.md/E1Zqw https://archive.md/E1Zqw
- dhosek 5y ago
  You could learn about a non-paternal event, I suppose.
  - dymk 5y ago
    That’s literally why I did 23andme, and I found out some very interesting things about my family structure.